Ajovy is one of the CGRP inhibitors used for migraine prevention. Approved for ages 6 and up, it's noted for its safety, tolerability, and benefits seen within the first month.

Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly ...

Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...